Why I do not treat patients for mild disease.

Christophe HEZODE,

Liver Int 01/01/2016;36 suppl 1 : 13-20 10.1111/liv.13019.

Ideal oral combinations to eradicate HCV: The role of ribavirin.

Christophe HEZODE, JP Bronowicki,

J Hepatol. 01/01/2016;64(1) : 215-225 10.1016/j.jhep.2015.09.009. 26/09/2015

Fusion of Information from 3D Printing and Surgical Robot: An Innovative Minimally Technique Illustrated by the Resection of a Large Celiac Trunk Aneurysm

C Salloum, C Lim, L Fuentes, M Osseis, Alain LUCIANI, D Azoulay,

World J Surg 01/01/2016;40(1) : 245-247 10.1007/s00268-015-3218-y.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

JJ Feld, IM Jacobson, Christophe HEZODE, T Asselah, PJ Ruane, N Gruener, A Abergel, A Mangia, CL Lai, HL Chan, F Mazzotta, C Moreno, E Yoshida, SD Shafran, WJ Towner, TT Tran, J McNally, A Osinusi, E Svarovskaia, Y Zhu, DM Brainard, JG McHutchison, K Agarwal, S Zeuzem,

N Engl J Med. 31/12/2015;373(27) : 2599-2607 10.1056/NEJMoa1512610. 16/11/2015

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.

F About, T Oudot-Mellakh, J Niay, P Rabiega, V Pedergnana, D Duffy, P Sultanik, C Cagnot, F Carrat, P Marcellin, F Zoulim, D Larrey, Christophe HEZODE, H Fontaine, JP Bronowicki, S Pol, ML Albert, I Theodorou, A Cobat, L Abel,

PLoS One. 15/12/2015;10(12) : e0145105 10.1371/journal.pone.0145105.

Virologic Tools for HCV Drug Resistance Testing.

Slim FOURATI, Jean-Michel PAWLOTSKY,

Viruses. 04/12/2015;7(12) : 6346-6359 10.3390/v7122941.

Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C".

Jean-Michel PAWLOTSKY, A Aghemo, D Back, G Dusheiko, X Forns, M Puoti, C Sarrazin,

J Hepatol. 01/12/2015;63(6) : 1535-1536 10.1016/j.jhep.2015.09.004 12/09/2015

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.

J Boursier, A Ducancelle, J Vergniol, P Veillon, V Moal, C Dufour, JP Bronowicki, D Larrey, Christophe HEZODE, F Zoulim, H Fontaine, V Canva, T Poynard, S Allam, V De Ledinghen,

J Viral Hepat. 01/12/2015;22(12) : 1002-1010 10.1111/jvh.12433. 27/07/2015

Therapy: Avoiding treatment failures associated with HCV resistance.

Jean-Michel PAWLOTSKY,

Nat Rev Gastroenterol Hepatol. 01/12/2015;12(12) : 673-674 10.1038/nrgastro.2015.184 27/10/2015

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

C Soulie, L Assoumou, Mélanie MERCIER-DARTY, Christophe RODRIGUEZ, F Donati, S Sayon, G Peytavin, MA Valantin, F Caby, L Schneider, A Canestri, D Costagliola, C Katlama, V Calvez, AG Marcelin,

J Antimicrob Chemother. 01/12/2015;70(12) : 3339-3344 10.1093/jac/dkv280 22/09/2015